News | News By Subject | News by Disease News By Date | Search News

Graft vs. Host Disease News Articles

Get Our FREE
Industry eNewsletter
Top Breaking News
AbbVie (ABBV) Nabs Breakthrough Tag for Ibrutinib to Treat Chronic Graft-Versus-Host-Disease     6/29/2016
FDA Bestows Incyte (INCY)'s Ruxolitinib with Breakthrough Tag for Graft-Versus-Host Disease     6/23/2016
Chimerix (CMRX) Shares Plunge After Brincidofovir Fails in Phase III Trial     12/29/2015
Fate Therapeutics (FATE) Discontinues Development of ProHema in Patients Undergoing Cord Blood HCT     12/7/2015
AmerisourceBergen Corporation (ABC) the “Pony to Ride” for Biosimilar Opportunities, Says UBS     3/16/2015
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014
Best Value In Biotech? Actavis (ACT), Says UBS     11/17/2014
Rigel Pharmaceuticals, Inc. (RIGL) Experimental Eye Drug R348 Fails Mid-Stage Study     8/14/2014
DOR BioPharma, Inc. (DORB) Receives Guidance From FDA on Proposed Confirmatory Phase 3 Clinical Trial Design of orBec(R) in GI GVHD     11/10/2008
DOR BioPharma, Inc. (DORB) Has Voluntarily Withdrawn European Marketing Authorization Application (MAA) For Orbec(R) For The Treatment Of Gastrointestinal Graft-Versus-Host Disease (GI GVHD)     5/22/2008
Osiris Therapeutics, Inc. (OSIR) (Jobs) Receives FDA Fast Track Status for Prochymal(TM) as First-Line Treatment for Acute GvHD     12/10/2007
FDA Advisory Panel Advises Against DOR BioPharma, Inc. (DORB)'s orBec(R) Approval     5/10/2007
FDA Advisory Committee To Review DOR BioPharma, Inc. (DORB)'s orBec(R) For The Treatment Of GI GVHD     1/31/2007
Pharming Group (PHGUF.PK)'s Lead Drug Receives Orphan Drug Designations From The FDA; Shares Soar     6/14/2006
Osiris Therapeutics, Inc. First To Announce FDA Fast Track Designation For A Stem Cell Product; Decision Seen As A Positive Sign For Both Osiris And The Emerging Stem Cell Industry     1/31/2005

News from Around the Web
Treatment May Limit Graft-Versus-Host Disease, Universitatsklinikum Freiburg Study     8/20/2009
Embryonic Stem Cells Reduce Transplantation Rejection, University of Iowa Study     9/16/2008
Bone Marrow Transplants: Cancer Drug Shows Promise Against Graft Vs. Host Disease in University of Michigan Study     7/17/2008
Immune Molecule that Plays a Powerful Role in Avoiding Organ Rejection Identified in Medical College of Georgia Study     6/20/2008
Mesenchymal Stem Cells Can Suppress Life-Threatening Immune Reaction, Karolinska Institute and Karolinska University Hospital Study     5/14/2008
Uncooked Fish Linked with Liver Cancer in Asia -- Graft-Versus-Host Disease     7/10/2007
Study Shows Rituximab Effective In Treating Chronic Graft-Versus-Host Disease     3/24/2006
New Tissue "Grown Within Minutes"     10/17/2005
Transplant Rejection Averted By Simple Light Exposure In Stanford Animal Study     5/7/2004
Level Of Immune Cells Predict Chances Against Leukemia     3/19/2004
Drugs Limit Deadly Side Effects Of Graft-Versus-Host Disease     3/1/2004

Press Releases
Janssen R&D Release: Late-breaking Phase 2 Ibrutinib Study In Chronic Graft-Versus-Host-Disease (cGVHD) Showed Complete Or Partial Response In Up To Two-Thirds Of Steroid Dependent Or Refractory Patients     12/6/2016
AbbVie (ABBV) Release: Late-Breaking Ibrutinib (IMBRUVICA) Data Show Complete Or Partial Response In Two-Thirds Of Patients With Chronic Graft-Versus-Host-Disease, A Frequent And Potentially Life-Threatening Complication Of Stem Cell Transplant     12/6/2016
Kamada Ltd. (KMDA) Announces Plan For Phase II/III Clinical Trial With Alpha-1 Antitrypsin IV For Treatment Of Graft-Versus-Host Disease     11/2/2016
Xenikos: Last Patient Treated In Phase 1/2 Trial With T-Guard In Acute Graft-Versus-Host Disease     9/15/2016
Alexion (ALXN) Release: European Commission (EC) Grants Orphan Drug Designation To ALXN1007 For The Treatment Of Patients With Graft-Versus-Host Disease (GVHD)     8/30/2016
FDA Grants Orphan-Drug Designation For Regenicin, Inc.'s NovaDerm Cultured Skin Substitute     8/30/2016
Janssen Pharmaceutical Companies Release: Ibrutinib (IMBRUVICA) Granted Breakthrough Therapy Designation By FDA For The Development Of A Treatment For Chronic Graft-Versus-Host Disease (cGVHD)     6/29/2016
Fate Therapeutics (FATE) Announces FDA Fast Track Designation For Protmune     6/20/2016
Kamada Ltd. (KMDA)’s Alpha-1 Antitrypsin Now Available To Treat Graft-Versus-Host Disease On MyTomorrows Early Access Platform     5/25/2016
Alexion (ALXN) Release: Researchers To Present Late-Breaking Data On ALXN1210 In Patients With PNH At European Hematology Association Annual Congress     5/19/2016
Incyte (INCY) Reports 2016 First-Quarter Financial Results And Updates Shareholders On Key Clinical Programs     5/9/2016
Kamada Ltd. (KMDA) Reports 2016 First Quarter Financial Results     5/9/2016
Kiadis Pharma Presents Positive Data On The Primary Endpoint Of Its Single Dose Phase II Trial With ATIR101     4/4/2016
BioLineRx Ltd. Announces Initiation Of Phase 2 Trial For BL-8040 As Novel Stem Cell Mobilization Treatment     3/23/2016
Quark Pharmaceuticals Inc. Doses First Patients In Two Pivotal Phase III Studies And One Phase II Study Of RNAi-Based Therapeutics For Kidney And Eye Indications     3/14/2016